Visit the News Center Even short interventions are associated with changes in the risk of heart attack, stroke, and death Sarah Moser and Alaska Adams/Washio Medicine WashU drug researchers have found that stopping GLP-1 drugs like semaglutide and terzepatide — even temporarily — increases the risk of heart attack, stroke and death compared to staying … Read more
Welcome to The Thin Line, a New York Post series on the dark side of GLP-1 drugs. Although GLP-1 agonists sold under brand names like Ozympic have helped millions of people lose weight, manage diabetes and improve other health conditions, they are not without risks. Check back for more stories about the lesser-known downsides of … Read more
Wu’s administration is considering cutting GLP-1 coverage for weight loss for Boston city workers because of “skyrocketing” health insurance costs that are straining city finances. Chief Finance Officer Ashley Groffenberger said in a letter to the Boston City Council on Monday that the city has confirmed that there will be a significant increase in employee … Read more